Clinical research gives hope to patients with Alzheimer's

Clinical research gives hope to patients with Alzheimer's

On the other side of the Atlantic Ocean, the lab has just completed the second phase of clinical trials of the drug against Alzheimer's disease. According to researchers, the results are very encouraging.

A new hope for people with Alzheimer's.

According to Alzheimer's, about 50 million people around the world are suffering from Alzheimer's disease, and about 10 million new cases are reported each year, the disease, which affects the elderly mostly, is the most common cause of dementia and is thought to account for 60 to 70 per cent of the cases, and it is also noted that dementia is one of the main causes of disability and dependency among older persons around the world.

On January 11, 2021, U.S. lab Eli Lilly announced the completion of phase II of the Donnaemaba clinical study, a promising cure for Alzheimer's disease, whose results are a source of hope for patients.

Encouraging results at the dawn of phase III

The study involved 272 patients with an early stage of Alzheimer ' s disease; in the 76 weeks of Donnaemaba ' s treatment, their sedimentation of beta-amyloid proteins decreased by 32% compared to the patients of the control group; this is more than a significant improvement in the effectiveness of the drug.

Eli Lilley's lab officials have reported a reduction in the symptoms of the disease; this is a significant re-establishment of the cognitive functions of patients; the same is true of their vital functions; however, these improvements have not been observed at all control points; the laboratory is currently preparing for the third and final stage of clinical trials; the latter should concern at least 500 people.